Catalog3 refs
Melanotan I (MT-I)
OtherResearch use only
Educational use only. Not medical advice. Verify all information with primary sources and a licensed clinician before use.
Body Map
Skin
Overview
Synthetic analog of α-MSH that selectively targets MC1 receptors for melanin stimulation. FDA-approved as SCENESSE implant for erythropoietic protoporphyria (EPP). Research-grade injectable form enables flexible dosing versus the implant version.
Primary Uses
Enhanced tanning response
Photoprotection
Even pigmentation
Erythropoietic protoporphyria (EPP) treatment
Protocol Reference
Dose
Loading: 0.25-0.5mg daily; Maintenance: 0.25-0.5mg 2-3x weekly
Frequency
Loading phase: 1-2x daily for 1-2 weeks, then maintenance 2-3x weekly
Half-life
~30 minutes
Route
Subcutaneous injection · Nasal
Evidence
FDA Approved
Research Models
Human
Also in Other